CSL Ltd

CSL

Company Profile

  • Business description

    CSL is one of the largest global biotech companies and has three main segments. CSL Behring either uses plasma-derived proteins or recombinants to treat conditions including immunodeficiencies, bleeding disorders, and neurological indications. CSL Seqirus is the world’s second-largest influenza vaccination business and was acquired in fiscal 2016. CSL Vifor is an iron deficiency and nephrology business and was acquired in fiscal 2023. CSL has a strong R&D track record, and the product portfolio and pipeline include nonplasma products as the firm continues to broaden its scope. Originally formed in Australia as a government-owned entity, CSL now earns roughly half its revenue in North America and a quarter in Europe.

  • Contact

    655 Elizabeth Street
    MelbourneVIC3000
    AUS

    T: +61 393891911

    E: [email protected]

    https://www.csl.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    30 June 2026

    Employees

    29,904

CSL Ltd News & Analysis

investing

Podcast: Investing Compass

Morningstar Australia's podcast series.
stocks

Chart of the Week: Morningstar’s forecast for CSL’s future

We see gross margin expansion on efficiencies and limited tariff impact
personal-finance

4 income investing mistakes

Avoiding these mistakes will increase your chances of success as an income investor. 

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,190.207.50-0.08%
CAC 407,966.9571.010.90%
DAX 4024,113.62232.900.98%
Dow JONES (US)46,441.1043.210.09%
FTSE 1009,446.4396.001.03%
HKSE26,855.56232.680.87%
NASDAQ22,755.1695.150.42%
Nikkei 22544,783.24232.390.52%
NZX 50 Index13,423.6410.35-0.08%
S&P 5006,711.2022.740.34%
S&P/ASX 2008,899.606.20-0.07%
SSE Composite Index3,882.7820.250.52%

Market Movers